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Abstract
Background: Continuous positive airway pressure (CPAP) is used widely to provide respiratory support for
neonates, and is often the first treatment choice in tertiary centres. Recent trials have demonstrated that CPAP
reduces need for intubation and ventilation for infants born at 25-28 weeks gestation, and at > 32weeks, in non-
tertiary hospitals, CPAP reduces need for transfer to NICU. The aim of this study was to examine recent population
trends in the use of neonatal continuous positive airway pressure.
Methods: We undertook a population-based cohort study of all 696,816 liveborn neonates ≥24 weeks gestation in
New South Wales (NSW) Australia, 2001-2008. Data were obtained from linked birth and hospitalizations records,
including neonatal transfers. The primary outcome was CPAP without mechanical ventilation (via endotracheal
intubation) between birth and discharge from the hospital system. Analyses were stratified by age ≤32 and > 32 weeks
gestation.
Results: Neonates receiving any ventilatory support increased from 1,480 (17.9/1000) in 2001 to 2,486 (26.9/1000)
in 2008, including 461 (5.6/1000) to 1,465 (15.8/1000) neonates who received CPAP alone. There was a concurrent
decrease in mechanical ventilation use from 12.3 to 11.0/1000. The increase in CPAP use was greater among
neonates > 32 weeks (from 3.2 to 11.8/1000) compared with neonates ≤32 weeks (from 18.1 to 32.7/1000). The
proportion of CPAP > 32 weeks initiated in non-tertiary hospitals increased from 6% to 30%.
Conclusions: The use of neonatal CPAP is increasing, especially > 32 weeks gestation and among non-tertiary
hospitals. Recommendations are required regarding which infants should be considered for CPAP, resources
necessary for a unit to offer CPAP and monitoring of longer term outcomes.
Background
Continuous positive airway pressure (CPAP) is used
widely to provide respiratory support for neonates, and is
often the first treatment choice in tertiary centres [1,2].
There are multiple ways of providing CPAP (eg via under-
water bubble CPAP, flow driver or ventilator), different
patient interfaces (eg binasal prongs, a single nasopharyn-
geal prong, face mask, high flow nasal cannula) and var-
ious levels of water pressure may be used (usually 4-8 cm
water). For extremely preterm neonates, CPAP is an alter-
native to intubation and mechanical ventilation [3] and at
later gestational ages, CPAP may be an alternative to
headbox oxygen therapy [4]. CPAP is an attractive option
for supporting neonates with respiratory distress, because
it preserves spontaneous breathing, does not require endo-
tracheal intubation, and may result in less lung injury than
mechanical ventilation [2]. Older and larger neonates
appear to be managed effectively using CPAP as the initial
and primary method for support without the need for sur-
factant [1]. However, a significant proportion of neonates
born very preterm, particularly prior to 28 weeks, may
require combinations of respiratory support modes, which
could include surfactant treatment, endotracheal intuba-
tion and mechanical ventilation and/or CPAP.
Until recently, there was a lack of data from rando-
mized controlled trials (RCTs) on the effectiveness of
CPAP [4,5]. Between 2002 and 2006, Buckmaster and
colleagues conducted an RCT comparing CPAP with
headbox oxygen for neonates > 31 weeks born in non-
tertiary hospitals and found CPAP reduced the need for
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transfer to a neonatal intensive care unit (NICU) [6].
Trials in very preterm babies published since 2008 sug-
gest that starting CPAP at birth may have important ben-
efits, with 50% of babies 25-28 weeks gestation never
requiring intubation and ventilation, and that neonates of
this gestational age who commence CPAP from birth
have no increased risk of death or bronchopulmonary
dysplasia, and in fact are less likely to be on oxygen at 28
days of age [7,8].
Other potential advantages of CPAP compared with
intubation and subsequent conventional mechanical
ventilation include lower costs, easier operation, poten-
tially fewer risks, and less training [1]. Nevertheless,
CPAP is still considered resource-intensive, requiring
skilled and experienced staff to ensure the success of
the treatment [5] and may result in an increased risk of
pneumothorax and nasal trauma [6,8]. The aim of this
study was to use population data to examine statewide
trends in CPAP use. An additional aim was to assess
whether CPAP use changed in hospitals that partici-
pated in the Buckmaster CPAP trial [6].
Methods
Study population
The study population included all live births in New South
Wales (NSW), Australia, from January 2001 to December
2008 with a gestational age of at least 24 weeks and for
whom the birth record linked to at least one hospital
record. Neonates transferred interstate within 7 days of
birth (N = 585, < 0.1%) were excluded because no further
information was available for these neonates. New South
Wales is the most populous state in Australia with a popu-
lation of 7.2 million and over one-third of all Australian
births [9].
Data sources
The data for this study were obtained from the NSW Mid-
wives Data Collection (MDC) and the NSW Admitted
Patient Data Collection (APDC). The MDC (referred to as
‘birth’ records) is a population-based surveillance system
covering all livebirths and stillbirths in NSW. The infor-
mation is recorded by either the midwife or medical prac-
titioner attending the birth, and includes demographic,
medical and obstetric information on the mother and
information on the labour, delivery and condition of the
neonate. The APDC (referred to as ‘hospital’ records) is a
census of all inpatient admissions (public and private) in
NSW. It includes a range of demographic data and clinical
information. The diagnoses and procedures related to the
admission are coded according to the 10th revision of the
International Statistical Classification of Diseases and
Related Health Problems, Australian Modification (ICD-
10-AM) and the affiliated Australian Classification of
Health Interventions, respectively.
The birth record and the infant hospital record asso-
ciated with the birth were linked for each neonate. Hospi-
tal records were also linked longitudinally to identify
hospital-to-hospital transfers and readmissions. Probabilis-
tic record linkage was conducted independent of the
research by the NSW Centre for Health Record Linkage
[10]. No health information is used for linkage, and at no
time is identifying information made available to research-
ers. The study was approved by the NSW Population and
Health Services Research Ethics Committee.
Outcome and explanatory factors
The primary outcome was whether a neonate received
CPAP or mechanical ventilation (via endotracheal intu-
bation) between birth and initial discharge from the hos-
pital system, identified from any of 20 procedure fields in
any of the neonate’s hospital records. A NSW validation
study found that any mechanical ventilation and CPAP
are reliably reported in population health data [11]. For
analysis, neonates were classified as ‘ventilation’ if they
received mechanical ventilation, whether or not they
received CPAP, and as ‘CPAP’ if they received CPAP
alone and did not receive mechanical ventilation in the
period from birth to discharge from the hospital system.
Neonatal transfer to a NICU was a secondary outcome.
Hospitals were categorised as ‘tertiary’, ‘CPAP trial’
and ‘other non-tertiary’. Tertiary hospitals (n = 7) have
a Level III neonatal intensive care unit (NICU) which
provides mechanical ventilation and care for neonates
with severe and/or complex illness [12]. The CPAP trial
hospitals were the five NSW hospitals that participated
in the Buckmaster CPAP trial [6]. Participation in this
trial required a paediatric registrar onsite 24-hours and
nursing staff trained in use of CPAP for neonates. The
‘other non-tertiary’ hospitals (n = 78) included all other
public and private hospitals at which babies were born
in NSW, and have service levels ranging from general
practitioner or midwife care with low level neonatal care
to special care nurseries. The neonatal factors available
for analysis included gender, plurality (singleton vs mul-
tiple), gestational age, small for gestational age (SGA,
< 10th percentile) and large for gestational age (LGA,
> 90th percentile), [13] Apgar score less than 4 at 1
minute and Apgar score less than 7 at 5 minutes. Gesta-
tional age is reported in completed weeks of gestation as
determined by the best clinical estimate, including early
ultrasound (> 97%) and date of the last menstrual per-
iod. Only factors that are accurately reported were
included in the analyses [14-18].
Analysis
We determined rates of CPAP over time and by neonate
characteristics, gestational age and hospital of CPAP
initiation. Gestational age was categorised as ≤32 weeks
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and > 32 weeks, based on national policy recommending
neonates ≤32 weeks be delivered in tertiary centres [19].
Results
The study included 696,816 live births of at least 24 weeks
gestation born in NSW between 2001 and 2008, increasing
from 82,542 in 2001 to 92,461 in 2008. Of all infants,
191,511 (27.5%) were born at tertiary hospitals, 94,390
(13.5%) at CPAP-trial hospitals and 410,915 (59.0%) at
other non-tertiary hospitals. Overall 6,188 (8.9/1000 live-
births) neonates received CPAP alone and 8,229 (11.8/
1000) received mechanical ventilation with or without
CPAP, including 3,700 (5.3/1000) who received both
mechanical ventilation and CPAP. Compared to neonates
who did not receive any ventilatory support, those receiv-
ing CPAP alone were more likely to be male (59% versus
51%), of multi-fetal pregnancies (21% versus 3%), born at
< 37 weeks (69% versus 5%) and have low Apgar scores at
1 (10% versus 2%) and/or 5 minutes (9% versus 1%) (Table
1). Twins and triplets were 8.6 times more likely than sin-
gletons to receive CPAP alone, but after adjusting for
gestational age this risk decreased substantially (adjusted
RR: 1.13; 95% CI: 1.07-1.20). For the gestational ages 31
through 36 weeks, more neonates received CPAP alone
than were ventilated. Ventilation numbers only exceeded
CPAP alone at ≤30 weeks gestation (Table 1). The gesta-
tion-specific rates of CPAP alone were 261.9/1000 among
neonates ≤32 weeks, 51.3/1000 at 33-36 weeks and 2.9/
1000 at ≥37 weeks. Among infants who required respira-
tory support, those with transient tachypnea were more
than twice as likely to be managed with CPAP alone (RR =
2.5; 95% CI 2.3-2.7) compared to those with other diag-
noses; 65% of infants with transient tachypnea as one of
their admitting diagnoses and requiring respiratory sup-
port received CPAP alone.
The number and rate of neonates receiving any venti-
latory support increased from 1,480 (17.9/1000) in 2001
to 2,486 (26.9/1000) in 2008 (P < 0.001), including an
increase from 461 (5.6/1000) to 1,465 (15.8/1000) neo-
nates who received CPAP alone (P < 0.001) (Figure 1).
There was a concurrent decrease in any use of mechani-
cal ventilation from 12.3 to 11.0/1000 livebirths. How-
ever, there was no significant change in the use of
combined mechanical ventilation and CPAP (P = 0.52).
The relative increase in the use of CPAP alone was
greater among neonates > 32 weeks (increasing 3.7-fold
from 3.2/1000 in 2001 to 11.8/1000 livebirths in 2008)
compared with neonates aged ≤32 weeks (increasing
1.8-fold from 18.1 to 32.7/1000 livebirths) (Figure 2).
When examined by hospital of initiation, 89% of CPAP
was initiated in tertiary centres, including 8% that was
initiated following neonatal transfer. Although in abso-
lute numbers CPAP initiated in tertiary centres among
neonates > 32 weeks increased, the proportion provided
by tertiary hospitals declined from 94% (3.0/1000) in
2001 to 70% (8.3/1000) in 2008 (P < 0.001, Figure 3).
Compared with 2003-2006 (the period of Buckmaster
trial), the number of neonates > 32 weeks receiving
CPAP alone at the CPAP trial hospitals doubled in 2007.
From 2001 to 2006, between 3 (2.5%) and 11 (9.6%) other
non-tertiary hospitals provided CPAP to neonates (Figure
3). In 2007, this number had doubled, with 22 (23.4%)
hospitals providing CPAP to 56 neonates, and by 2008
further increased to 27 hospitals (28.1%) treating 222
infants. From 2001 to 2008, the proportion of neonates
born outside a tertiary centre and transferred to a NICU
declined slightly from 755 (1.2%) to 745 (1.1% P < 0.001).
Neonates who received CPAP at the CPAP trial hospitals
were significantly less likely to be transferred to a NICU
than neonates who received CPAP at other non-tertiary
hospitals (13.6% versus 20.1%, P = 0.03).
Discussion
Use of CPAP without mechanical ventilation for neonates
increased from 2001 to 2008, with a particularly notable
rise among infants of > 32 weeks gestation and at non-ter-
tiary hospitals in 2008. Although the rates of CPAP use
were highest among infants ≤30 weeks, in terms of abso-
lute numbers of neonates exposed, the burden was higher
among more mature neonates. The relatively slower
increase in CPAP use among neonates ≤32 weeks may
relate to greater difficulty in supporting very premature
neonates on CPAP alone without a period of mechanical
ventilation or may reflect the lack of evidence regarding
use of CPAP in very preterm neonates available during the
study period. Trials in very preterm neonates published
from 2008 support the consideration of CPAP as an alter-
native to intubation and surfactant, [7,8] and as these find-
ings are translated into practice we may see a further
increase in CPAP rates.
CPAP use among neonates > 32 weeks increased slowly
from 2001 through 2004, followed by greater increases,
particularly in 2008. During this period, there was no
increase in the temporal trend of births ≤32 or > 32
weeks gestation. The overall increase in neonates receiv-
ing CPAP was offset by a small decrease in rate of
mechanical ventilation, resulting in a significant increase
in total number of infants receiving ventilatory support
(CPAP or mechanical ventilation). This suggests that the
increase was primarily due to an increase in CPAP in
neonates who would previously have received only sup-
plemental oxygen in either a tertiary or non-tertiary unit.
The 2007 increase coincided with publication of the
Buckmaster CPAP trial results, which showed CPAP for
selected neonates at appropriately resourced non-tertiary
hospitals could reduce transfers to a NICU [6]. At the
hospitals involved in the CPAP trial the number of neo-
nates receiving CPAP doubled after the trial, implying
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that neonates who would previously have been rando-
mized to oxygen were instead being given CPAP.
The use of large, linked, validated population-based
databases that provide information on all neonates is a
strength of this study. However, these data do not have
detailed clinical information such as the severity of disease,
use of surfactant or the duration of CPAP. Furthermore,
the temporal sequence of events (eg CPAP, mechanical
ventilation, pneumothorax) cannot be determined, only
that the events occurred during an admission. This limits
the ability to assess complications or reasons for changes
in the respiratory support methods.
Nasal CPAP has been adopted by many NICUs as a
way of reducing rates of bronchopulmonary dysplasia in
premature neonates, but assessment of its benefits is
complicated by questions about the simultaneous effects
of concomitant surfactant treatments and other NICU
interventions [20]. Most research into the potential
benefit of CPAP has used a study population of very pre-
term or extremely preterm neonates who were delivered
in tertiary referral hospitals. Little is known about the
benefits of CPAP use in more mature neonates in tertiary
NICUs. The Buckmaster trial compared CPAP use with
supplemental oxygen in neonates > 30 weeks gestation in
non-tertiary centres [6] to prevent transfer of neonates
for intensive care. The study showed a reduction in both
treatment ‘failure’ (RR = 0.54; 95% CI 0.32, 0.91) and the
rate of up-transfer (RR = 0.51; 95% CI 0.31, 0.89), but did
not show any statistically significant reduction in out-
comes such as length of admission. The results also show
an increased risk of pneumothorax in the CPAP arm but
the confidence interval is wide (RR = 2.76; 95% CI 1.02,
7.48). The possibility of increased rates of pneumothorax
has been a concern with use of CPAP, and the COIN
trial [8] reported a rate of pneumothorax three times
higher in the CPAP group compared with the mechanical
Table 1 Characteristics of neonates receiving CPAP or mechanical ventilation, NSW 2001-2008
Infant and hospital characteristics CPAP alone Mechanical ventilation* No ventilation or CPAP
N = 6188 N = 8229 N = 682,399
n (%) n (%) n (%)
Male 3625 (58.6) 4908 (59.6) 350346 (51.3)
Female 2563 (41.4) 3321 (40.4) 332053 (48.7)
Singleton 4870 (78.7) 6846 (83.2) 663798 (97.3)
Multiple 1318 (21.3) 1383 (16.8) 18601 (2.7)
Gestational age
24-26 80 (1.3) 1008 (12.3) 207 (0.03)
27-29 559 (9.0) 1506 (18.3) 276 (0.04)
30-32 1734 (28.0) 1355 (16.5) 2337 (0.3)
33-34 1115 (18.0) 803 (9.8) 7598 (1.1)
35-36 800 (12.9) 682 (8.3) 26332 (3.9)
37-38 681 (11.0) 995 (12.1) 151713 (22.2)
39-40 803 (13.0) 1282 (15.6) 371034 (54.4)
41-42 413 (6.7) 597 (7.3) 122056 (17.9)
> 42 3 (0.05) 1 (0.01) 846 (0.12)
Size at birth
< 10th centile 636 (10.3) 1127 (13.7) 64996 (9.5)
10th-90th centile 4865 (78.6) 6241 (75.8) 545275 (79.9)
> 90th centile 687 (11.1) 861 (10.5) 72128 (10.6)
Apgar at 1 minute
< 4 626 (10.2) 2450 (30.1) 10011 (1.5)
≥4 5538 (89.8) 5701 (69.9) 670734 (98.5)
Apgar at 5 minutes
< 7 529 (8.6) 2375 (29.1) 6355 (0.9)
≥7 5634 (91.4) 5783 (70.9) 674538 (99.1)
* with or without CPAP
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ventilation group. However, the recently published
results of the SUPPORT trial found no difference in the
rates of pneumothorax for extremely preterm neonates
randomized to initial treatment with either CPAP or
endotracheal administration of surfactant [7]. Further,
the long term consequences of CPAP remain undeter-
mined and need to be monitored.
Although our findings highlight that most neonates
treated with CPAP are cared for in tertiary centres,
there was an increase in the proportion treated out-
side these hospitals. Our study found that most non-
tertiary non-CPAP-trial hospitals that provided CPAP
support treated relatively few neonates in 2007-2008;
and this may be inadequate to ensure safety and
Figure 1 Trend in ventilation and CPAP rates among neonates, NSW 2001-2008.
Figure 2 Trend in the CPAP rate per 1000 live births, by gestational age, NSW 2001-2008.
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cost-effectiveness of the intervention. CPAP is
resource-intensive and caution has been advised with
the use of CPAP in units that are not well staffed or
experienced in its use [21-23]. Furthermore, it is
important that the availability of CPAP facilities does
not lead to complacency regarding policies of antena-
tal transfer of high risk pregnancies, particularly as in
utero transfer has been demonstrated to be more ben-
eficial and improve neonate outcomes [24].
Buckmaster estimated that on average, across an neo-
natal population, a cost saving of ~AU$1,700 would
accrue for every neonate treated with CPAP [6]. How-
ever, increased use of CPAP is likely to increase costs at
an individual hospital if additional resources, such as
experienced staff and ongoing monitoring of CPAP neo-
nates, are required [2]. Additional costs associated with
CPAP use in non-tertiary hospitals may be offset by a
reduction in neonatal transfers, decreased length of stay
or better outcomes for neonates [24] and should be
investigated. Although the Buckmaster CPAP trial did
show a benefit in reduced transfers,[6] it is not known if
this remains true in the wider group of hospitals now
providing CPAP and among the potentially broader
group of neonates exposed, especially given the small
numbers treated at each hospital. Recommendations
should be developed regarding which neonates should
be considered for CPAP, and the appropriate resources
necessary for a unit to offer CPAP. In addition, longer
term outcomes for neonates who receive CPAP need to
be monitored.
Conclusions
CPAP use has increased since 2001, most notably
among neonates > 32 weeks and this represents an
extension of ventilatory support rather than replacement
of mechanical ventilation. Furthermore, CPAP use
appears to have increased in non-tertiary hospitals fol-
lowing publication of a randomized trial showing CPAP
decreased the need for neonatal transfer. Our study
highlights the need for recommendations about which
neonates should be considered for CPAP and the appro-
priate resources necessary to offer CPAP.
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